Deferiprone (L1) as an adjuvant therapy for Plasmodium falciparum malaria

D. Mohanty*, K. Ghosh, A. V. Pathare, D. Karnad

*Corresponding author for this work

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

Background & objectives: Mortality due to Plasmodium falciparum infection remains high in India, hence any modality of treatment which can improve the outcome of this disease is worth exploring. The present study was undertaken to see whether addition of an oral iron chelator, deferiprone (L1) to the conventional treatment regime for P. falciparum infection improves the clinical course and final outcome. Methods: In this prospective, randomised double blind trial, 45 consecutive patients with P. falciparum infection were randomised into two groups. Patients in Group I (control group, 21 patients) received standard quinine and doxycycline therapy along with supportive therapy and placebo capsules for 10 days. Patients in Group II (24 patients) received the same treatment as Group I but in place of placebo capsule received deferiprone capsules 75 mg/kg/day in 12 hourly divided doses. The parameters evaluated included the time taken in resolution of parasitaemia, fever and coma, differences in final outcome i.e., death or other severe complications, and side effects and deferiprone tolerance. Results: Four patients in Group I and two in Group II died (P>0.05). The resolution of fever and coma was significantly faster in Group II (P

Original languageEnglish
Pages (from-to)17-21
Number of pages5
JournalIndian Journal of Medical Research
Volume115
Issue numberJAN.
Publication statusPublished - 2002

Keywords

  • Adjuvant therapy
  • Deferiprone
  • Falciparum malaria
  • Iron chelation
  • Plasmodium falciparum

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Fingerprint Dive into the research topics of 'Deferiprone (L1) as an adjuvant therapy for Plasmodium falciparum malaria'. Together they form a unique fingerprint.

  • Cite this